c-Fos accelerates hepatocyte conversion to a fibroblastoid phenotype through ERK-mediated upregulation of paxillin-serine178 phosphorylation

Molecular Carcinogenesis

Volumn 48, Issue 6, 2009, Pages 532-544

  Güller, Meryem C ^a   André, Jocelyne ^a   Legrand, Agnès ^a   Setterblad, Niclas ^b   Mauviel, Alain ^a   Verrecchia, Franck ^a   Daniel, Fanny ^c   Bernuau, Dominique ^a,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

EGF R; Motility; Scattering

Indexed keywords

ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PAXILLIN; SERINE DERIVATIVE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL ACTIVATION; CELL MOTILITY; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; DOWN REGULATION; ENZYME INHIBITION; FIBROBLAST; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; LIVER CELL; LIVER CELL CARCINOMA; ONCOGENE C FOS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 65749102155     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20492     Document Type: Article

References (73)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
2. Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-374.
3. Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 1996;156:217-226. (Pubitemid 27072577)
4. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
5. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
6. Akhurst RJ, Derynck R. TGF-beta signaling in cancer - A double-edged sword. Trends Cell Biol 2001;11:S44-S51. (Pubitemid 33001443)
7. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623. (Pubitemid 36899145)
8. Reynisdottir I, Polyak K, Iavarone A, et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9:1831-1845.
9. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004;29:265-273.
10. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-693. (Pubitemid 41740650)
11. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: Implications for carcinogenesis. Oncogene 2005;24:5742-5750.
12. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005;118:3573-3584.
13. Lee MK, Pardoux C, Hall MC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007;26:3957-3967.
14. Bedossa P, Peltier E, Terris B, et al. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995;21:760-766.
15. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, et al. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 1998;28:717-726.
16. Factor VM, Kaao CY, Santoni-Rugiu E, et al. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997;57:2089-2095.
17. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129. (Pubitemid 32952643)
18. Muraoka-Cook RS, Dumont N, Artegea CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s-943s. (Pubitemid 40111109)
19. Del Castillo G, Murillo MM, Alvarez-Barrientos A, et al. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: Role of EGF receptor ligands. Exp Cell Res 2006;312:2860-2871.
20. Davies M, Robinson M, Smith E, et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005;95:918-931.
21. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
22. Grande M, Franzen A, Karlsson JO, et al. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci 2002;115:4227-4236.
23. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003;4:657-665. (Pubitemid 36934968)
24. Xie L, Law BK, Chytil AM, et al. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004;6:603-610.
25. Seton-Rogers SE, Lu Y, Hines LM, et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004;101:1257-1262.
26. Ueda Y, Wang S, Dumont N, et al. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 2004;279:24505-24513.
27. Fujimoto K, Sheng H, Shao J, et al. Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp Cell Res 2001;266:239-249.
28. Murillo MM, del Castillo G, Sanchez A, et al. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 2005;24:4580-4587.
29. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: Steps towards invasiveness. J Cell Sci 2002;115:1189-1202.
30. Fischer AN, Herrera B, Mikula M, et al. Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis. Carcinogenesis 2005;26:931-942.
31. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400. (Pubitemid 32531297)
32. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-868.
33. Ozanne BW, Spence HJ, McGarry L, et al. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007;26:1-10.
34. Ozanne BW, McGarry L, Spence HJ, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000;36:1640-1648.
35. Malliri A, Symons M, Hennigan RF, et al. The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J Cell Biol 1998;143:1087-1099. (Pubitemid 28547406)
36. Angel P, Szabowski A. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. Biochem Pharmacol 2002;64:949-956. (Pubitemid 35238032)
37. Johnston IM, Spence HJ, Winnie JN, et al. Regulation of a multigenic invasion programme by the transcription factor, AP-1: Re-expression of a down-regulated gene, TSC-36, inhibits invasion. Oncogene 2000;19:5348-5358.
38. Rutberg SE, Adams TL, Glick A, et al. Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes. Cancer Res 2000;60:6332-6338.
39. Mejlvang J, Kriajevska M, Berditchevski F, et al. Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Exp Cell Res 2007;313:380-393.
40. Saez E, Rutberg SE, Mueller E, et al. c-fos is required for malignant progression of skin tumors. Cell 1995;82:721-732.
41. Eger A, Stockinger A, Schaffhauser B, et al. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000;148:173-188.
42. Scott LA, Vass JK, Parkinson EK, et al. Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. Mol Cell Biol 2004;24:1540-1559.
43. Tkach V, Tulchinsky E, Lukanidin E, et al. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 2003;22:5045-5054. (Pubitemid 37026402)
44. Schippers IJ, Moshage H, Roelofsen H, et al. Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. Cell Biol Toxicol 1997;13:375-386.
45. Brown JJ, Parashar B, Moshage H, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 2000;31:173-181.
46. Sadowski HB, Gilman MZ. Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 1993;362:79-83. (Pubitemid 23087296)
47. Miao GG, Curran T. Cell transformation by c-fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 1994;14:4295-4310. (Pubitemid 24160836)
48. Hennigan RF, Hawker KL, Ozanne BW. Fos-transformation activates genes associated with invasion. Oncogene 1994;9:3591-3600. (Pubitemid 24359397)
49. Yanagisawa K, Osada H, Masuda A, et al. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 1998;17:1743-1747.
50. Brown KA, Aakre ME, Gorska AE, et al. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res 2004;6:R215-231.
51. Tumbarello DA, Brown MC, Hetey SE, et al. Regulation of paxillin family members during epithelial-mesenchymal transformation: A putative role for paxillin delta. J Cell Sci 2005;118:4849-4863.
52. Zaidel-Bar R, Milo R, Kam Z, et al. A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions. J Cell Sci 2007;120:137-148.
53. Nakamura K, Yano H, Uchida H, et al. Tyrosine phosphorylation of paxillin alpha is involved in temporospatial regulation of paxillin-containing focal adhesion formation and F-actin organization in motile cells. J Biol Chem 2000;275:27155-27164.
54. Zenz R, Scheuch H, Martin P, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-889. (Pubitemid 36676039)
55. Mialon A, Sankinen M, Soderstrom H, et al. DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol 2005;25:5040-5051.
56. Ashktorab H, Daremipouran M, Wilson M, et al. Transactivation of the EGFR by AP-1 is induced by helicobacter pylori in gastric cancer. AmJ Gastroenterol 2007;102:2135-2146.
57. Isfort RJ, Cody DB, Stuard SB, et al. The combination of epidermal growth factor and transforming growth factor-beta induces novel phenotypic changes in mouse liver stem cell lines. J Cell Sci 1997;110:3117-3129.
58. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000;2:E231-E236.
59. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004;6:154-161.
60. Brown MC, Turner CE. Paxillin: Adapting to change. Physiol Rev 2004;84:1315-1339.
61. Ku H, Meier KE. Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells. J Biol Chem 2000;275:11333-11340. (Pubitemid 30212783)
62. Ishibe S, Joly D, Liu ZX, et al. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004;16:257-267.
63. Cai X, Li M, Vrana J, et al. Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement. Mol Cell Biol 2006;26:2857-2868.
64. Huang C, Jacobson K, Schaller MD. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004;3:4-6. (Pubitemid 40268573)
65. Spence HJ, McGarry L, Chew CS, et al. AP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteins. Mol Cell Biol 2006;26:1480-1495.
66. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-E136. (Pubitemid 34521026)
67. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
68. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000;11:23-35. (Pubitemid 30169723)
69. Mikula M, Gotzmann J, Fischer AN, et al. The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 2003;22:6725-6738.
70. Amicone L, Spagnoli FM, Spath G, et al. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J 1997;16:495-503.
71. Schuermann M, Hennig G, Muller R. Transcriptional activation and transformation by chimaeric Fos-estrogen receptor proteins: Altered properties as a consequence of gene fusion. Oncogene 1993;8:2781-2790.
72. Ching YP, Leong VY, Lee MF, et al. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res 2007;67:3601-3608.
73. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.